,
Gray, Laura J.
Brady, Emer M.
Albaina, Olatz
Edwardson, Charlotte L.
Harrington, Deirdre
Khunti, Kamlesh
Miksza, Joanne
Raposo, João Filipe
Smith, Ellesha
Vazeou, Andriani
Vergara, Itziar
Weihrauch-Blüher, Susann
Davies, Melanie J.
Funding for this research was provided by:
European Union
Article History
Received: 30 October 2018
Accepted: 16 July 2019
First Online: 25 July 2019
Ethics approval and consent to participate
: Favourable ethical opinion was granted for this study within all countries participating, the full name of each ethical committee and the date ethical approval was granted is given below per country. All parents/guardian’s provided written informed consent and all children assent prior to data collection.Germany: Ethic Committee of the Medical Faculty, University of Leipzig, 8/10/14Greece: Administrative Council of the Children Hospital Panagiotis & Aglaia Kyriakou, 26/11/14Portugal: Portuguese Diabetes Association Ethics Committee, 10/11/15Spain: Basque Ethical Committee, 13/04/15UK: East Midlands - Leicester South Research Ethics Committee, 17/12/15.
: Not applicable.
: M.J.D. reports personal fees from Novo Nordisk, Sanofi-Aventis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International and grants from Novo Nordisk, Sanofi-Aventis, Eli Lilly, Boehringer Ingelheim, and Janssen. KK (Chair) and MJD were members of the NICE Guidance Development Group, PH 38. No financial disclosures were reported by any of the other authors of this paper.